Top

Published in:

01-10-2019 | Topic Paper

Diagnostic biomarkers in non-muscle invasive bladder cancer

Authors: Izak Faiena, Charles J. Rosser, Karim Chamie, Hideki Furuya

Published in: World Journal of Urology | Issue 10/2019

Abstract

Successful treatment of non-muscle invasive bladder cancer (NMIBC) relies heavily on our ability to accurately detect disease typically in the presence of hematuria as well as to detect the early recurrent tumors in patients with a history of NMIBC. Unfortunately, the current biomarker landscape for NMIBC is a work in progress. Cystoscopy continues to be the gold standard, but can still miss 10% of tumors. Therefore, physicians frequently use additional tools to aid in the diagnosis of bladder cancer, such as urinary cytology. The urinary cytology is a good option for high-grade disease; however, it is limited by low sensitivity in detecting low-grade disease, as well as variable interpretation among cytopathologists. Thus, the limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. In this non-systematic review, we discuss the performance, potential advantages or disadvantages of these tests, and the future direction of biomarkers in NMIBC.

Karaoglu I, van der Heijden AG, Witjes JA (2014) The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol 32:651–659PubMed

Mowatt G, N’Dow J, Vale L, Nabi G, Boachie C, Cook JA et al (2011) Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care 27:3–10CrossRef

Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q (2012) Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int 110:E680–E687CrossRef

Soria F, Droller MJ, Lotan Y, Gontero P, D’Andrea D, Gust KM et al (2018) An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol 8:362

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 198:552–559CrossRef

Rosser CJ, Urquidi V, Goodison S (2013) Urinary biomarkers of bladder cancer: an update and future perspectives. Biomark Med. 7:779–790CrossRef

Papanicolaou GN, Marshall VF (1945) Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 101:519–520CrossRef

Xie Q, Huang Z, Zhu Z, Zheng X, Liu J, Zhang M et al (2016) Diagnostic value of urine cytology in bladder cancer. A meta-analysis. Anal Quant Cytopathol Histpathol. 38:38–44PubMed

Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 33(66):e25–e31

10.

Elias K, Svatek RS, Gupta S, Ho R, Lotan Y (2010) High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer 116:2954–2959CrossRef

11.

Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DF et al (2016) The Paris system for reporting urinary cytology: the quest to develop a standardized terminology. Acta Cytol 60:185–197CrossRef

12.

Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF et al (2005) Complement factor H as a marker for detection of bladder cancer. Clin Chem 51:856–863CrossRef

13.

Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser CJ (2012) Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol 30:869–873CrossRef

14.

Goodison S, Rosser CJ, Urquidi V (2013) Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther. 17:71–84CrossRef

15.

He D, Zeng C, Brinkley BR (1995) Nuclear matrix proteins as structural and functional components of the mitotic apparatus. Int Rev Cytol 162B:1–74PubMed

16.

Budman LI, Kassouf W, Steinberg JR (2008) Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2:212–221CrossRef

17.

Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y et al (2005) Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293:810–816CrossRef

18.

Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klatte T, Shariat SF (2014) Prospective external validation of a bladder cancer detection model. J Urol 192:1343–1348CrossRef

19.

Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ (2012) Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol. 12:23CrossRef

20.

Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK et al (2011) Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 117:2892–2897CrossRef

21.

Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J et al (2010) ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol 32:45–52PubMed

22.

Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, Hennenlotter J et al (2012) Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol 61:185–192CrossRef

23.

Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E et al (2013) uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol. 121:392–397CrossRef

24.

Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 26:646–651CrossRef

25.

Kim PH, Sukhu R, Cordon BH, Sfakianos JP, Sjoberg DD, Hakimi AA et al (2014) Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. BJU Int. 114:354–359CrossRef

26.

Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC et al (2000) A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164:1768–1775CrossRef

27.

Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I et al (2015) Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? World J Urol 33:1309–1313CrossRef

28.

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R (2008) Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 179:2164–2169CrossRef

29.

Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y (2010) Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 183:62–67CrossRef

30.

Lotan Y, O’Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C et al (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 35(531):e15–e22

31.

Kavalieris L, O’Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E et al (2017) Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol 197:1419–1426CrossRef

32.

Ritter R, Hennenlotter J, Kuhs U, Hofmann U, Aufderklamm S, Blutbacher P et al (2014) Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer. Urol Oncol. 32:337–344CrossRef

33.

Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W, Heidegger I (2017) Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: results from a prospective single-center study. Int J Med Sci. 14:811–819CrossRef

34.

van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL et al (2017) Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urol 197:590–595CrossRef

35.

Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S et al (2016) A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. J Transl Med. 14:287CrossRef

36.

Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y et al (2018) Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. Oncotarget. 9:7101–7111CrossRef

37.

Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S et al (2016) Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. World J Urol 34:1405–1409CrossRef

38.

Todenhofer T, Hennenlotter J, Guttenberg P, Mohrhardt S, Kuehs U, Esser M et al (2015) Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer. 15:155CrossRef

39.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Cancer Bladder et al (2017) Version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:1240–1267CrossRef

40.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461CrossRef

41.

Lei T, Zhao X, Jin S, Meng Q, Zhou H, Zhang M (2013) Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. Clin Genitourin Cancer. 11:56–62CrossRef

42.

Li C, Li H, Zhang T, Li J, Liu L, Chang J (2014) Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis. Biochem Biophys Res Commun 446:1047–1052CrossRef

43.

Kumar P, Nandi S, Tan TZ, Ler SG, Chia KS, Lim WY et al (2015) Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 6:13539–13549PubMedPubMedCentral

44.

Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ et al (1996) Bladder cancer-associated nuclear matrix proteins. Cancer Res 56:1690–1694PubMed

45.

Santoni M, Catanzariti F, Minardi D, Burattini L, Nabissi M, Muzzonigro G et al (2012) Pathogenic and diagnostic potential of BLCA-1 and BLCA-4 nuclear proteins in urothelial cell carcinoma of human bladder. Adv Urol. 2012:397412CrossRef

46.

Myers-Irvin JM, Landsittel D, Getzenberg RH (2005) Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 174:64–68CrossRef

47.

Cai Q, Wu Y, Guo Z, Gong R, Tang Y, Yang K et al (2015) Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget. 6:37500–37510PubMedPubMedCentral

48.

Andreadis C, Touloupidis S, Galaktidou G, Kortsaris AH, Boutis A, Mouratidou D (2005) Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol 174:1771–1775 (discussion 5–6) CrossRef

49.

Washino S, Hirai M, Matsuzaki A, Kobayashi Y (2011) Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma. Urol Int 87:420–428CrossRef

50.

Huang YL, Chen J, Yan W, Zang D, Qin Q, Deng AM (2015) Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis. Tumour Biol 36:3137–3145CrossRef

51.

Fernandez-Gomez J, Rodriguez-Martinez JJ, Barmadah SE, Garcia Rodriguez J, Allende DM, Jalon A et al (2007) Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 51:1267–1274CrossRef

52.

Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW et al (2003) Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23:3327–3331PubMed

53.

Liang Z, Xin R, Yu Y, Wang R, Wang C, Liu X (2018) Diagnostic value of urinary survivin as a biomarker for bladder cancer: a systematic review and meta-analysis of published studies. World J Urol 36(9):1373–1381. https://doi.org/10.1007/s00345-018-2285-8 CrossRefPubMed

54.

Leiblich A (2017) Recent developments in the search for urinary biomarkers in bladder cancer. Curr Urol Rep. 18:100CrossRef

55.

Roupret M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M et al (2008) A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int. 101:1448–1453CrossRef

56.

Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5:e13821CrossRef

57.

Roperch JP, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I et al (2016) Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer. 16:704CrossRef

58.

Larre S, Camparo P, Comperat E, Gil Diez De Medina S, Roupret M, Traxer O et al (2011) staging, and grading of urothelial carcinomas from urine: performance of BCA-1, a mini-array comparative genomic hybridisation-based test. Eur Urol 59:250–257CrossRef

59.

Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL et al (2002) Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464–470PubMed

60.

Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P (2004) Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10:1887–1893CrossRef

61.

Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W et al (2006) Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98:996–1004CrossRef

62.

Abern MR, Owusu R, Inman BA (2014) Clinical performance and utility of a DNA methylation urine test for bladder cancer. Urol Oncol. 32(51):e21–e26

63.

Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S et al (2017) Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol 72:952–959CrossRef

64.

Scott SN, Ostrovnaya I, Lin CM, Bouvier N, Bochner BH, Iyer G et al (2017) Next-generation sequencing of urine specimens: a novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin. Cancer Cytopathol. 125:416–426CrossRef

65.

Khetrapal P, Lee MWL, Tan WS, Dong L, de Winter P, Feber A et al (2018) The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: a systematic review. Cancer Treat Rev 66:56–63CrossRef

66.

Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681CrossRef

67.

Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D et al (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 28:655–661CrossRef

68.

Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ et al (2012) An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 107:123–128CrossRef

69.

O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L et al (2012) A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 188:741–747CrossRef

70.

Mengual L, Burset M, Ribal MJ, Ars E, Marin-Aguilera M, Fernandez M et al (2010) Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res 16:2624–2633CrossRef

71.

Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W et al (2018) Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 121:29–37CrossRef

72.

Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ (2012) A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev 21:2149–2158CrossRef

73.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S et al (2018) Optimal trial design for studying urinary markers in bladder cancer: a collaborative review. Eur Urol Oncol 1(3):223–230CrossRef

74.

Solomon JPKKA, Hansel DE (2018) Emerging molecular approaches in the analysis of urine in bladder cancer diagnosis. In: Hansel D, Lerner S (eds) precision molecular pathology of bladder cancer. Molecular Pathology Library, Springer, Cham

Title: Diagnostic biomarkers in non-muscle invasive bladder cancer
Authors: Izak Faiena
Charles J. Rosser
Karim Chamie
Hideki Furuya
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 10/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2567-1

At a glance: The STEP trials

Springer Medicine

Diagnostic biomarkers in non-muscle invasive bladder cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2019

A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer

Non-muscle invasive bladder cancer (NMIBC): boiling arena and promissory future

Robot-assisted laparoscopic pyeloplasty (RALP) in children with horseshoe kidneys: results of a multicentric study

Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression

Transurethral incision as initial option in treatment guidelines for ectopic ureteroceles associated with duplex systems

Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse